Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Importance of Salvage Surgery

被引:42
|
作者
Hamaji, Masatsugu [1 ]
Chen, Fengshi [1 ]
Matsuo, Yukinori [2 ]
Ueki, Nami [2 ]
Hiraoka, Masahiro [2 ]
Date, Hiroshi [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan
基金
日本学术振兴会;
关键词
Non-small-cell lung cancer; Surgery; Radiotherapy; Chemotherapy; POSITRON-EMISSION-TOMOGRAPHY; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; THORACOSCOPIC LOBECTOMY; TUMOR RECURRENCE; F-18-FDG PET/CT; HIGH-RISK; RESECTION; FAILURE; OUTCOMES;
D O I
10.1097/JTO.0000000000000662
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Many efforts have been made to detect local relapse (LR) in the follow-up after stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC) although limited data are available on its treatment and prognosis. We aimed to characterize treatment options and clarify long-term outcomes of isolated LR after SBRT for patients with clinical stage I NSCLC. Methods: We reviewed our institutional database in search of patients with isolated LR after SBRT for clinical stage I NSCLC at our institution between 1999 and 2013. Patient characteristics were compared with Mann-Whitney U test, (2) test, or Fisher's exact test as appropriate. Survival outcomes were estimated with Kaplan-Meier method. Potential prognostic factors were investigated using Cox proportional hazard model. Results: Of 308 patients undergoing SBRT for clinical stage I NSCLC, 49 patients were identified to have isolated LR. Twelve patients underwent salvage surgery, none underwent radiotherapy, and eight patients received chemotherapy, whereas 29 patients received best supportive care. No patient characteristic except operability was significantly related with patient selection for LR treatments. Five-year overall survival (OS) rate of the whole cohort was 47.9% from SBRT and 25.7% from LR. Salvage surgery was associated with improved OS after LR (p = 0.014), and 5-year OS for patients undergoing salvage surgery was 79.5% from LR. Conclusions: It was confirmed that our patient selection for salvage surgery for isolated LR was associated with favorable survival outcomes. Operability based on multidisciplinary conferences, rather than measurable patient characteristics, is essential for appropriate patient selection for salvage surgery.
引用
收藏
页码:1616 / 1624
页数:9
相关论文
共 50 条
  • [1] Salvage Surgery for Isolated Local Recurrence after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small Cell Lung Cancer
    Date, Hiroshi
    Hamaji, Masatsugu
    Matsuo, Yukinori
    Yoshizawa, Akihiko
    Menju, Toshi
    Chen-Yoshikawa, Toyofumi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1390 - S1391
  • [2] Nodal recurrences after stereotactic body radiotherapy for early stage non-small-cell lung cancer
    Tibdewal, Anil
    Pathak, Rima S.
    Agarwal, Jai Prakash
    Hoskote, Sumedh S.
    Mummudi, Naveen
    Iyer, Veena
    Nair, Akshay G.
    CURRENT PROBLEMS IN CANCER, 2021, 45 (02)
  • [3] Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review
    Dickhoff, Chris
    Schaap, Pedro M. Rodriguez
    Otten, Rene H. J.
    Heymans, Martijn W.
    Heineman, David J.
    Dahele, Max
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [4] Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer
    Mayne, Nicholas R.
    Lin, Belle K.
    Darling, Alice J.
    Raman, Vignesh
    Patel, Deven C.
    Liou, Douglas Z.
    D'Amico, Thomas A.
    Yang, Chi-Fu Jeffrey
    ANNALS OF SURGERY, 2020, 272 (06) : 925 - 929
  • [5] Salvage surgery to treat tumor regrowth after stereotactic body radiotherapy in primary non-small cell lung cancer
    Koizumi, Takahisa
    Aoki, Tadashi
    Saito, Masayuki
    Yamato, Yasushi
    Furuyashiki, Go
    Kitahara, Akihiko
    Hashimoto, Takehisa
    Watanabe, Takehiro
    Tsuchida, Masanori
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 5289 - 5298
  • [6] Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy
    Milano, Michael T.
    Kong, Feng-Ming
    Movsas, Benjamin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (01) : 78 - 87
  • [7] Different Mortality after Surgery and stereotactic Body Radiotherapy for early-stage non-small-cell Lung Cancer
    Borm, Kai J.
    Combs, Stephanie E.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (06) : 600 - 601
  • [8] Stereotactic Body Radiotherapy Versus Surgery for Early-Stage Non-Small-Cell Lung Cancer
    Li, Hui
    Shen, Yefeng
    Wu, Yuanzhou
    Cai, Shaoru
    Zhu, Yaru
    Chen, Siping
    Chen, Xin
    Chen, Qunqing
    JOURNAL OF SURGICAL RESEARCH, 2019, 243 : 346 - 353
  • [9] Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer
    Stokes, William A.
    Bronsert, Michael R.
    Meguid, Robert A.
    Blum, Matthew G.
    Jones, Bernard L.
    Koshy, Matthew
    Sher, David J.
    Louie, Alexander, V
    Palma, David A.
    Senan, Suresh
    Gaspar, Laurie E.
    Kavanagh, Brian D.
    Rusthoven, Chad G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) : 642 - +
  • [10] Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non-Small-Cell Lung Cancer
    Kilburn, Jeremy M.
    Lester, Scott C.
    Lucas, John T., Jr.
    Soike, Michael H.
    Blackstock, A. William
    Kearns, William T.
    Hinson, William H.
    Miller, Antonius A.
    Petty, William J.
    Munley, Michael T.
    Urbanic, James J.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 572 - 576